GlassScriptPhysician profile
Lawrence M Kasper
NPI 1083656581
$559.83
in general payments reported to CMS, 2019-2025
16 companies · $32.48 in 2025
The $32.48 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $108 · 2021: $11.92 · 2022: $179 · 2025: $32.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $32.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $32.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $177.91 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $66.55 | 2019-2020 | |
| Amgen INC. | $62.64 | 2019 | |
| Daiichi Sankyo INC. | $32.80 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $32.48 | 2025 | Alymsys |
| Pfizer INC. | $31.46 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.20 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $17.35 | 2019 | |
| Secura Bio, INC. | $17.15 | 2019 | |
| Kite Pharma, INC. | $16.84 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.59 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.10 | 2019 | |
| Celgene Corporation | $14.03 | 2019 | |
| Incyte Corporation | $13.58 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $11.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Kasper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.